Type to search

Stephen C. Glover

Share
Stephen C. Glover
Co-founder, Chief Executive Officer, and Chairman
ZyVersa Therapeutics

Stephen C. Glover

Mr. Glover has over 35+ years of business experience in biopharmaceuticals and life sciences. Currently Mr. Glover is Co-Founder, Chairman, President and CEO of ZyVersa Therapeutics. Before founding ZyVersa, Mr. Glover was Co-Founder and CBO of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins, a biosimilar company, as well as Chief Business Officer of Insmed Incorporated.

Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of Andrx Labs which developed and marketed products in metabolic diseases and Men’s Health and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health.

Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. He has demonstrated results in start ups, large cap and turnarounds with a focus on business strategy, commercial execution, product development, business transformation and corporate development. He has over 25 life sciences transactions totaling over $10 billion in licensing and M&A activities and has raised over $250M in capital. His strategic and operational experience includes strategic planning, corporate development, operations management, product development, product marketing and sales management.

Currently Mr. Glover serves on the Board of Directors of ZyVersa, Chairman of PDS Biotechnology, Asclepius Lifesciences and Tack Surgical.

Posts Featuring Stephen C. Glover


Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: Illegal string offset 'ID' in /home/customer/www/pharmtechfocus.com/public_html/wp-content/themes/magplus-child/single-people.php on line 101

Warning: addcslashes() expects parameter 1 to be string, array given in /home/customer/www/pharmtechfocus.com/public_html/wp-includes/wp-db.php on line 1539
ZyVersa Therapeutics and University of Miami Awarded a Grant From the Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation With IC100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology | Pharmtech Focus

ZyVersa Therapeutics and University of Miami Awarded a Grant From the Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation With IC100 Blocks Neuroinflammation Driving Parkinson’s Disease Pathology